EyePoint Pharmaceuticals Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- EyePoint Pharmaceuticals's estimated revenue is currently $3M per year.
- EyePoint Pharmaceuticals received $60.0M in venture funding in February 2019.
- EyePoint Pharmaceuticals's estimated revenue per employee is $26438
- EyePoint Pharmaceuticals's total funding is $86M.
- EyePoint Pharmaceuticals has 112 Employees.
- EyePoint Pharmaceuticals grew their employee count by 107% last year.
- EyePoint Pharmaceuticals currently has 11 job openings.
|Paul Ashton||President, Chief Executive Officer and a Director|
|Len Ross||VP Finance/Chief Accounting Officer|
|Marty Nazzaro||Senior Vice President Operations|
|Jack Weet||Senior Vice President, Regulatory Affairs and Quality|
|Nancy Lurker||President and Chief Executive Officer|
|Thomas Hadley||VP - Head of Marketing and Sales|
|Jianbing Chen||VP, Research|
|LeBlanc Ron||Director of Operations|
|Rod Riedel||VP, Regulatory Affairs|
|David Kowalsky||Director, Market Access and Patient Services|
What Is EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products. As a leading provider of miniaturized, sustained-release drug delivery products, we focus on improving the lives of patients with serious eye disorders in indications with high unmet medical need. With 3 FDA-approved sustained release treatments in ophthalmology we continue to push the evolution of our Durasert Technology platform to further enhance treatments for wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
EyePoint Pharmaceuticals News
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting ...
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the target of a significant increase in short interest during the month of July. As of July 31st, ...
On its latest session, EyePoint Pharmaceuticals, Inc. ($EYPT) opened at 1.45, reaching a high of 1.55 and a low of 1.43 before closing at a ...
EyePoint Pharmaceuticals Funding
|2011-01-20||$10.8M||Undisclosed||Rodman & Renshaw LLC||Article|
|2012-08-03||$5.4M||Undisclosed||Rodman & Renshaw LLC||Article|
|2019-02-14||$60.0M||Undisclosed||CR Group L.P.||Article|
EyePoint Pharmaceuticals Executive Hires
|2018-11-28||Ron Honig||SVP General Counsel & Company Secretary||Article|